aducanumab

Notice Regarding Biogen’s Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer’s Disease

ruth 23 April

1 minute

TOKYO, Apr 23, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that Biogen (Nasdaq: BIIB) has disclosed, in its Q1 2021 Earnings Press Release issued on […]

JCN Newswire

Eisai: Biogen Files New Drug Application for Aducanumab in Japan

ruth 11 December

2 minutes

TOKYO, Dec 11, 2020 – (JCN Newswire) – Biogen and Eisai, Co., Ltd. (Tokyo, Japan) announced that Biogen has submitted a Japanese New Drug Application (J-NDA) to the Ministry of […]